Sesen Bio Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$124.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Sesen Bio's estimated annual revenue is currently $10.4M per year.(i)
  • Sesen Bio received $9.0M in venture funding in March 2018.
  • Sesen Bio's estimated revenue per employee is $167,500
  • Sesen Bio's total funding is $124.9M.

Employee Data

  • Sesen Bio has 62 Employees.(i)
  • Sesen Bio grew their employee count by -9% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.2M1-99%N/AN/A
#2
$3.1M20233%N/AN/A
#3
$21.5M13918%$351MN/A
#4
$18M1165%$312.8MN/A
#5
$235M418-23%$340.9MN/A
#6
$2.2M3417%N/AN/A
#7
$6M40-9%$176.5MN/A
#8
$109.4M70614%N/AN/A
#9
$6.2M40233%N/AN/A
#10
$1.9M12-20%N/AN/A

We are passionate in our commitment to improving and renewing people's lives. Sesen Bio is a late-stage company developing fusion protein medicines for people with cancer. Our fusion protein approach tethers a tumor-targeting antibody fragment to a protein cytotoxic payload to form a single protein molecule designed to selectively and broadly kill cancer cells while sparing healthy cells and to activate the body's innate immune response system. The most advanced program in our pipeline is Vicinium, a novel investigational anti-cancer treatment that has the potential to treat multiple cancers driven by overexpression of EpCAM, such as non-muscle invasive bladder (NMIBC) and squamous cell carcinoma of the head and neck (SCCHN). We are currently advancing Vicinium in a Phase 3 registration trial for the treatment of people with NMIBC who have been previously treated with bacillus Calmette-Guérin (BCG), with positive three-month efficacy results established and 12-month study results expected in mid-2019. Due to Vicinium's potential to promote an anti-tumor immune response, we believe it holds promise as a combination treatment with immuno-oncology drugs, such as checkpoint inhibitors. The first assessment of this is in a clinical study combing Vicinium with AstraZeneca's durvalumab, in NMIBC. For more information, please visit www.sesenbio.com.

keywords:Biotechnology,Cleantech,Healthcare,Marketing,Pharmaceuticals,Wind Power

$124.9M

Total Funding

62

Number of Employees

$10.4M

Revenue (est)

-9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Sesen Bio News

2022-04-20 - Sesen Bio (NASDAQ:SESN) Lifted to “Hold” at Zacks Investment ...

Sesen Bio (NASDAQ:SESN) Lifted to “Hold” at Zacks Investment Research. Posted by admin on Apr 23rd, 2022. Share on Twitter Share on Facebook Share on...

2022-04-06 - Do Analysts Expect Sesen Bio Inc (SESN) Stock to Rise After It Is Lower By -4.84% in a Month?

Analysts who follow Sesen Bio Inc (SESN) on average expect it to add 18.64% over the next twelve months. Those same analysts give the stock...

2022-03-30 - Sesen Bio updates on resubmission plans for Vicineum marketing application

Clinical-stage biotech, Sesen Bio (NASDAQ:SESN), is trading higher in the pre-market Thursday after the company updated on its resubmission...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.1M62114%N/A
#2
$8.1M6229%N/A
#3
$18.9M6235%$379.7M
#4
$4M62-9%$69M
#5
$8.4M6235%N/A

Sesen Bio Funding

DateAmountRoundLead InvestorsReference
2010-02-18$35.0MAFlagship Ventures, Third Rock VenturesArticle
2012-05-09$20.0MUndisclosedJAFCO Co LtdArticle
2014-11-26$20.0MUndisclosedCitigroup Global Markets IncArticle
2017-11-03$8.0MUndisclosedH.C. Wainwright & Co., LLCArticle
2018-03-22$9.0MUndisclosedArticle